Karydas Daphne
- SEC CIK
- 0001816952
In the past year, 4 open-market sale filings worth $925.6K and no purchases.
Current role at each company
- MLYS Mineralys Therapeutics, Inc.Directoras of Sep 17, 2026
- CMPS COMPASS Pathways plcDirectoras of May 29, 2026
- LogicBio Therapeutics, Inc.Directoras of Nov 17, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $925.6K
- 4 filings
- Net
- −$925.6K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Karydas Daphne as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
MLYS Mineralys Therapeutics, Inc.
Director4 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 (view filing)5:41 PM ET | Sep 15 | 2 days | Karydas DaphneDirector | SSale | −3.00K | $28.58 | −$85.7K | −32.6%6.20K after | 10b5-1 |
| Jun 17, 2026 (view filing) | Jun 17 | Same day | Karydas DaphneDirector | SSale | −3.00K | $25.00 | −$75.0K | −32.6%6.20K after | 10b5-1 |
| Apr 2, 2026 (view filing) | Mar 31 | 2 days | Karydas DaphneDirector | SSale | −3.00K | $25.00 | −$75.0K | −32.6%6.20K after | 10b5-1 |
| Nov 13, 2025 (view filing) | Nov 13 | Same day | Karydas DaphneDirector | SSale | −15.0K | $45.99 | −$689.8K | −100.0%0 after | 2 lots |